These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8067203)

  • 21. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
    Ren R
    Oncogene; 2002 Dec; 21(56):8629-42. PubMed ID: 12476309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abl: the prototype of oncogenic fusion proteins.
    Saglio G; Cilloni D
    Cell Mol Life Sci; 2004 Dec; 61(23):2897-911. PubMed ID: 15583852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
    EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
    Melo JV; Deininger MW
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of knowledge-based therapy for cancer: identification of unique targets.
    Rao SG
    Natl Med J India; 1998; 11(6):301-2. PubMed ID: 10083808
    [No Abstract]   [Full Text] [Related]  

  • 29. Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ
    Rev Invest Clin; 2004; 56(5):605-8. PubMed ID: 15776864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can clues to the molecular defects in chronic myelogenous leukemia come from genetic studies on the Abelson tyrosine kinase in fruit flies?
    Comer AR; Liebl EC; Hoffmann FM
    J Lab Clin Med; 1995 Jun; 125(6):686-91. PubMed ID: 7769362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human Philadelphia chromosome-positive chronic myeloid leukemia: a potential model for antisense therapy.
    De Lord C; Clutterbuck RD; Powles RL; Min T; Titley JC; Millar JL
    Exp Hematol; 1993 Jun; 21(6):826-8. PubMed ID: 8500581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P; Calabretta B
    Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
    [No Abstract]   [Full Text] [Related]  

  • 33. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.
    Muller AJ; Young JC; Pendergast AM; Pondel M; Landau NR; Littman DR; Witte ON
    Mol Cell Biol; 1991 Apr; 11(4):1785-92. PubMed ID: 2005881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
    Sawyers CL
    Leuk Lymphoma; 1993; 11 Suppl 2():101-3. PubMed ID: 8124222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular biological pathophysiology of chronic myelogenous leukemia].
    Nishimura J
    Fukuoka Igaku Zasshi; 1995 Feb; 86(2):19-23. PubMed ID: 7729779
    [No Abstract]   [Full Text] [Related]  

  • 36. Problem-solving test: signal transduction in Philadelphia chromosome positive leukemia cells.
    Szeberényi J
    Biochem Mol Biol Educ; 2012; 40(5):333-6. PubMed ID: 22987556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL1 in leukemia: disguise master outplays riding shotgun.
    Rana A; Ali GM; Ali S; Khan A; Mansoor S; Malik S; Farooqi AA
    J Cancer Res Ther; 2013; 9(1):6-10. PubMed ID: 23575066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BCR gene and philadelphia chromosome-positive leukemogenesis.
    Laurent E; Talpaz M; Kantarjian H; Kurzrock R
    Cancer Res; 2001 Mar; 61(6):2343-55. PubMed ID: 11289094
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of the hybrid Bcr/Abl kinase in the pathogenesis of chronic myeloid leukemia lacking C-Abl and CXCR4 proteins.
    Polishchuk LA; Telegeev GD
    Exp Oncol; 2014 Sep; 36(3):138-43. PubMed ID: 25265345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations.
    Pane F; Intrieri M; Quintarelli C; Izzo B; Muccioli GC; Salvatore F
    Oncogene; 2002 Dec; 21(56):8652-67. PubMed ID: 12476311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.